For example, NCT01400451 is investigating the efficacy and safety of vemurafenib (BRAF inhibitor) in combination with ipilimumab (CTLA-4-Ab) for the treatment of patients with metastatic melanoma expressing an activated mutant form of BRAF V600E [38]. Here, BRAF is linked to metastatic melanoma.